Tibotec Pharmaceuticals' protease inhibitor darunavir [PREZISTA] has received conditional marketing authorisation from the European Commission

Source: Inpharma, Volume 1, Number 1576, 2007-02-24 , pp. 23-23(1)

Publisher: Adis International

Keywords: Darunavir, therapeutic use; Development-status; HIV-1-infections, treatment; Research-and-development; Tibotec-Pharmaceuticals

Document Type: Short communication

Publication date: 2007-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers